BGBC016 STK11 NSCLC (Non-Small Cell Lung Cancer)

BGBC016 STK11 NSCLC (Non-Small Cell Lung Cancer)

Es posible que algunos contenidos no estén disponibles en español.

Purpose of this Study

We are doing this study to find out if an investigational drug called bemcentinib (the study drug) is a safe and effective option when it is combined with the standard therapy for non-small cell lung cancer (1 immunotherapy drug and 2 chemotherapy drugs).

Who Can Participate?

Eligibility

Adults ages 18+ who are diagnosed with advanced non-squamous non-small cell lung cancer. For more information about who can be in this study, please contact the study team at annmarie.peters@duke.edu.

What is Involved?

Description

If you join this study, you will go through a screening period to make sure you are eligible. During the screening period you will:
  • Have blood draws
  • Have imaging scans (CT and MRI)
  • Have 2 procedures to check your heart function, an electrocardiogram (ECG) and either an echocardiogram (ECHO) or a multigated acquisition scan (MUGA)
If you are eligible to get the study drug, you will:
  • Take the study drug by month once per day
  • Received the standard therapy (1 immunotherapy drug and 2 chemotherapy drugs) every 21 days by injection into a vein (IV)

    • Study Details

    Full Title

    Phase 1b/2a safety and tolerability study of bemcentinib with pembrolizumab/carboplatin/pemetrexed in subjects with untreated advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without/with a STK11 mutation. (BGBC016 STK11 NSCLC)

    Principal Investigator

    Laura
    Alder

    Protocol Number

    PRO00112972

    NCT ID

    NCT05469178

    Phase

    I/II

    Enrollment Status

    Open to Enrollment
    ClinicalTrials.gov